by Chinese Academy of SciencesNeuronal C/EBPβ escalation shortens the life span of mice, leading to neural excitation. Credit: SIATCognitive decline during normal aging is exacerbated in neurodeg
by Chinese Academy of SciencesNeuronal C/EBPβ escalation shortens the life span of mice, leading to neural excitation. Credit: SIATCognitive decline during normal aging is exacerbated in neurodeg
by Kate Clark,University College LondonCredit: Pixabay/CC0 Public DomainA team of students and doctors, led by UCL medic Hamzah Selim, has launched an innovative app which uses fun brain games t
by Kate Clark,University College LondonCredit: Pixabay/CC0 Public DomainA team of students and doctors, led by UCL medic Hamzah Selim, has launched an innovative app which uses fun brain games t
by ElsevierFigure 1. Linear Mixed Effect Models displaying effects of pathology at baseline over time on the development of neuropsychiatric symptoms Plots of estimated marginal means and 95% CI
by ElsevierFigure 1. Linear Mixed Effect Models displaying effects of pathology at baseline over time on the development of neuropsychiatric symptoms Plots of estimated marginal means and 95% CI
by Perelman School of Medicine at the University of PennsylvaniaPET scan of a human brain with Alzheimer's disease. Credit: public domainDelivering the medication dantrolene through the nose
by Perelman School of Medicine at the University of PennsylvaniaPET scan of a human brain with Alzheimer's disease. Credit: public domainDelivering the medication dantrolene through the nose
by Melissa Rohman,Northwestern UniversityLeft: Neuron at the motor cortex of a C9ORF72 patient stained for MAP2 and rRNA, showing the pattern of expression of ribosomal RNA in a human neuron mos
by Melissa Rohman,Northwestern UniversityLeft: Neuron at the motor cortex of a C9ORF72 patient stained for MAP2 and rRNA, showing the pattern of expression of ribosomal RNA in a human neuron mos
by Valerie Goodwin,University of MichiganCredit: CC0 Public DomainFor patients with multiple sclerosis, a regular exercise routine is important for managing symptoms. But due to different causes
by Valerie Goodwin,University of MichiganCredit: CC0 Public DomainFor patients with multiple sclerosis, a regular exercise routine is important for managing symptoms. But due to different causes
by Cedars-Sinai Medical CenterCredit: CC0 Public DomainIn a study led by Cedars-Sinai, researchers have discovered two types of brain cells that play a key role in dividing continuous human exper
by Cedars-Sinai Medical CenterCredit: CC0 Public DomainIn a study led by Cedars-Sinai, researchers have discovered two types of brain cells that play a key role in dividing continuous human exper
by Alzheimer's AssociationPET scan of a human brain with Alzheimer's disease. Credit: public domainTwo articles published online today byAlzheimer's & Dementia: Translational Res
by Alzheimer's AssociationPET scan of a human brain with Alzheimer's disease. Credit: public domainTwo articles published online today byAlzheimer's & Dementia: Translational Res
by University of California, Los AngelesCredit: Unsplash/CC0 Public DomainHighly targeted electrical stimulation to the brain showed promise as a new treatment for the most common type of stroke,
by University of California, Los AngelesCredit: Unsplash/CC0 Public DomainHighly targeted electrical stimulation to the brain showed promise as a new treatment for the most common type of stroke,
by Katherine Fenz,Rockefeller UniversityEasySci enables high-throughput and low-cost single-cell transcriptome and chromatin accessibility profiling across the entire mammalian brain. Credit:&nb
by Katherine Fenz,Rockefeller UniversityEasySci enables high-throughput and low-cost single-cell transcriptome and chromatin accessibility profiling across the entire mammalian brain. Credit:&nb
Biogen said it was discontinuing Aduhelm to put more resources into Leqembi, a newer Alzheimer's medicine that was fully approved in 2023 under the traditional regulatory pathway.A controversial A
Biogen said it was discontinuing Aduhelm to put more resources into Leqembi, a newer Alzheimer's medicine that was fully approved in 2023 under the traditional regulatory pathway.A controversial A